The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Enhanced CAR–T cell activity against solid tumors by vaccine boosting through the chimeric receptor
Open accessAbstract
A boost for CAR–T cells: Chimeric antigen receptor (CAR)–T cell immunotherapy has been highly successful for treating certain blood cancers. Yet this approach has been a challenge for solid tumors, in part because it is difficult to target functional engineered T cells to the tumor site. Ma et al. designed a vaccine strategy to improve the efficacy of CAR–T cells by restimulating the CAR directly within the native lymph node microenvironment (see the Perspective by Singh and June). Injected “amph-ligand” vaccines promoted synthetic antigen presentation and led to CAR–T cell activation, expansion, and increased tumor killing. The system could potentially be applied to boost any CAR–T cell. Science , this issue p. 162 ; see also p. 119
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
How to calculate sample size in animal studies?
Charan, J., & Kantharia, N. D. (2013) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.119726 · Cited by 1,881
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831
Kochenderfer, J. N., Wilson, W. H., Janik, J. E., Dudley, M. E., Stetler-Stevenson, M., Feldman, S. A., Maric, I., Raffeld, M., Nathan, D.-A. N., Lanier, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281931 · Cited by 1,337
Sotillo, E., Barrett, D. M., Black, K. L., Bagashev, A., Oldridge, D., Wu, G., Sussman, R., Lanauze, C., Ruella, M., Gazzara, M. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1020 · Cited by 1,254
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
Structure-based programming of lymph-node targeting in molecular vaccines
Liu, H., Moynihan, K. D., Zheng, Y., Szeto, G. L., Li, A. V., Huang, B., Van Egeren, D. S., Park, C., & Irvine, D. J. (2014) · Nature · doi:10.1038/nature12978 · Cited by 943
Self-citationThe future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
CAR T Cell Therapy for Solid Tumors
Newick, K., O'Brien, S., Moon, E., & Albelda, S. M. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-062315-120245 · Cited by 909
Adachi, K., Kano, Y., Nagai, T., Okuyama, N., Sakoda, Y., & Tamada, K. (2018) · Nature Biotechnology · doi:10.1038/nbt.4086 · Cited by 792
Sixt, M., Kanazawa, N., Selg, M., Samson, T., Roos, G., Reinhardt, D. P., Pabst, R., Lutz, M. B., & Sorokin, L. (2005) · Immunity · doi:10.1016/j.immuni.2004.11.013 · Cited by 747
Vaccines for established cancer: overcoming the challenges posed by immune evasion
van der Burg, S. H., Arens, R., Ossendorp, F., van Hall, T., & Melief, C. J. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.16 · Cited by 709
Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity
Boder, E. T., Midelfort, K. S., & Wittrup, K. D. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.170297297 · Cited by 673
Self-citationZah, E., Lin, M.-Y., Silva-Benedict, A., Jensen, M. C., & Chen, Y. Y. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0231 · Cited by 607
Gretz, J. E., Norbury, C. C., Anderson, A. O., Proudfoot, A. E. I., & Shaw, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.10.1425 · Cited by 583
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
Guedan, S., Posey, A. D., Shaw, C., Wing, A., Da, T., Patel, P. R., McGettigan, S. E., Casado-Medrano, V., Kawalekar, O. U., Uribe-Herranz, M., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96976 · Cited by 580
Moynihan, K. D., Opel, C. F., Szeto, G. L., Tzeng, A., Zhu, E. F., Engreitz, J. M., Williams, R. T., Rakhra, K., Zhang, M. H., Rothschilds, A. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4200 · Cited by 524
Self-citationPhan, T. G., Green, J. A., Gray, E. E., Xu, Y., & Cyster, J. G. (2009) · Nature Immunology · doi:10.1038/ni.1745 · Cited by 425
Sampson, J. H., Choi, B. D., Sanchez-Perez, L., Suryadevara, C. M., Snyder, D. J., Flores, C. T., Schmittling, R. J., Nair, S. K., Reap, E. A., Norberg, P. K., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0709 · Cited by 291
Versatile strategy for controlling the specificity and activity of engineered T cells
Ma, J. S. Y., Kim, J. Y., Kazane, S. A., Choi, S.-H., Yun, H. Y., Kim, M. S., Rodgers, D. T., Pugh, H. M., Singer, O., Sun, S. B., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524193113 · Cited by 273
Erratum: The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.65 · Cited by 191
Davila, M. L., Kloss, C. C., Gunset, G., & Sadelain, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061338 · Cited by 185
Liu, H., Kwong, B., & Irvine, D. J. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201101266 · Cited by 140
Self-citationMa, L., Shan, Y., Bai, R., Xue, L., Eide, C. A., Ou, J., Zhu, L. J., Hutchinson, L., Černý, J., Khoury, H. J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009073 · Cited by 136
Self-citationSlaney, C. Y., von Scheidt, B., Davenport, A. J., Beavis, P. A., Westwood, J. A., Mardiana, S., Tscharke, D. C., Ellis, S. L., Prince, H. M., Trapani, J. A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1860 · Cited by 123
Tanaka, M., Tashiro, H., Omer, B. A., Lapteva, N., Ando, J., Ngo, M. C., Mehta, B., Dotti, G., Kinchington, P. R., Leen, A. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2138 · Cited by 104
Wang, X., Wong, C. W., Urak, R. Z., Mardiros, A., Budde, L. E., Chang, W.-C., Thomas, S. H., Brown, C. E., Rosa, C. L., Diamond, D. J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2920 · Cited by 71
Fitz, C. D. V., Jensen, K. C., Nitta, R. T., Shain, A. H., Giacomini, C. P., & Wong, A. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2656 · Cited by 61
A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors
Oliveira, S. N. D., Wang, J., Ryan, C., Morrison, S. L., Kohn, D. B., & Hollis, R. P. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-23 · Cited by 39
Cited by
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
Melief, C. J. M., van Hall, T., Arens, R., Ossendorp, F., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,164
Neoantigens: promising targets for cancer therapy
Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01270-x · Cited by 1,020
Enhancing cancer immunotherapy with nanomedicine
Irvine, D. J., & Dane, E. L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0269-6 · Cited by 882
Self-citationRecent advances and discoveries in the mechanisms and functions of CAR T cells
Larson, R. C., & Maus, M. V. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00323-z · Cited by 852
Metadata
- Authors
- Ma, L., Dichwalkar, T., Chang, J. Y. H., Cossette, B., Garafola, D., Zhang, A. Q., Fichter, M., Wang, C., Liang, S., Silva, M., Kumari, S., Mehta, N. K., Abraham, W., Thai, N., Li, N., Wittrup, K. D., & Irvine, D. J.
- Venue
- Science
- Published
- 2019-07-12
- Volume
- 365
- Issue
- 6449
- Pages
- 162-168
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2957969985
- Cited by
- 439
- References
- 29
- FWCI
- 17.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.